Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Total Current Liabilities (2021 - 2025)

Senti Biosciences has reported Total Current Liabilities over the past 5 years, most recently at $14.0 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 6.3% year-over-year to $14.0 million; the TTM value through Dec 2025 reached $14.0 million, up 6.3%, while the annual FY2025 figure was $14.0 million, 6.3% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $14.0 million at Senti Biosciences, up from $12.0 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $18.1 million in Q4 2022 and troughed at $61025.0 in Q2 2021.
  • A 5-year average of $10.7 million and a median of $10.7 million in 2025 define the central range for Total Current Liabilities.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 29065.1% in 2022 and later plummeted 41.42% in 2023.
  • Year by year, Total Current Liabilities stood at $14.5 million in 2021, then grew by 24.14% to $18.1 million in 2022, then decreased by 29.81% to $12.7 million in 2023, then grew by 3.74% to $13.1 million in 2024, then increased by 6.3% to $14.0 million in 2025.
  • Business Quant data shows Total Current Liabilities for SNTI at $14.0 million in Q4 2025, $12.0 million in Q3 2025, and $10.0 million in Q2 2025.